NCT04281498 - Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions

Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation

Interventions

DRUG

Ruxolitinib

Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count

DRUG

Enasidenib

50mg -100mg daily

Trial Locations (11)

10029

Icahn School of Medicine at Mount Sinai, New York

10065

Memorial Sloan-Kettering Cancer Center, New York

27157

Wake Forest Baptist Health, Winston-Salem

33612

Moffitt Cancer Center, Tampa

44195

Taussig Cancer Center Institute, Cleveland

66205

University of Kansas Cancer Center, Westwood

78229

Mays Cancer Center at UT Health San Antonio, San Antonio

85259

Mayo Clinic - Arizona, Scottsdale

90048

Cedars-Sinai Medical Center, Los Angeles

48109-5936

University of Michigan Rogel Cancer Center, Ann Arbor

M5G 2M9

Princess Margaret Cancer Centre, Toronto